Publications by authors named "Melinda H Spooner"
Article Synopsis
- - Nonalcoholic fatty liver disease (NAFLD) is a significant global health issue, and understanding its progression could help develop new treatment strategies.
- - A study on Ldlr-/- mice showed that a western diet (WD) rapidly decreased essential fatty acids (EFAs) and increased markers of inflammation linked to the development of nonalcoholic steatohepatitis (NASH) within just one week.
- - The research suggests that monitoring and addressing EFA levels early on could potentially reduce the severity of NASH, as hepatic inflammation is closely associated with this condition.
Article Synopsis
- * The study examined male and female mice on a western diet (WD) for either 1 week or 40 weeks, finding that only those on the WD for 40 weeks showed clear signs of nonalcoholic steatohepatitis (NASH), including liver fat accumulation and fibrosis.
- * RNA sequencing revealed significant changes in gene expression within just 1 week of the WD, indicating early markers of disease linked to inflammation and metabolic syndrome, suggesting that early detection through gene targeting could help prevent disease progression.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide, particularly in obese and type 2 diabetic individuals. Currently, there are no therapies for NAFLD that have been approved by the US Food and Drug Administration. Herein, we examine the rationale for using ω3 polyunsaturated fatty acids (PUFAs) in NAFLD therapy.
View Article and Find Full Text PDFNonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide. NAFLD ranges in severity from benign steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and primary hepatocellular cancer (HCC). Obesity and type 2 diabetes mellitus (T2DM) are strongly associated with NAFLD, and the western diet (WD) is a major contributor to the onset and progression of these chronic diseases.
View Article and Find Full Text PDFBackground: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, particularly in obese and type 2 diabetic individuals. NAFLD ranges in severity from benign steatosis to nonalcoholic steatohepatitis (NASH); and NASH can progress to cirrhosis, primary hepatocellular carcinoma (HCC) and liver failure. As such, NAFLD has emerged as a major public health concern.
View Article and Find Full Text PDFOmega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Curr Opin Clin Nutr Metab Care
March 2019
Purpose Of Review: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide. The incidence of NAFLD parallels the prevalence of obesity. Moreover, NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and primary hepatocellular cancer (HCC).
View Article and Find Full Text PDF